Biotechnology
Medical
Biopharmaceutical

Mirati Therapeutics

$73.23
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$2.12 (-2.81%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell MRTX and other stocks, options, ETFs, and crypto commission-free!

About

Mirati Therapeutics, Inc. Common Stock, also called Mirati Therapeutics, is a clinical-stage oncology company, which engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Read More Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.

Employees
63
Headquarters
San Diego, California
Founded
1995
Market Cap
2.38B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
590.14K
High Today
$75.99
Low Today
$73.12
Open Price
$74.80
Volume
203.42K
52 Week High
$80.00
52 Week Low
$24.65

Collections

Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
Cancer Prevention
Health
Therapy
Technology

News

MarketBeatMar 8

Stock Price, News, & Analysis for Mirati Therapeutics

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administ...

30
Yahoo FinanceFeb 25

Analysis: Positioning to Benefit within Biogen, Mirati Therapeutics, PLDT, Zebra Technologies, Domino's Pizza, and Solar Capital — Research Highlights Growth, Revenue, and Consolidated Results

NEW YORK, Feb. 25, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Biogen Inc. (BIIB), Mirati Therapeutics, Inc. (MRTX), PLDT Inc. (PHI), Zebra Technologies Corporation (ZBRA), Domino's Pizza Inc (DPZ), and Solar Capital Ltd. (SLRC), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research. C...

104
Simply Wall StFeb 23

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Insiders Have Been Selling

Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! We’ve lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So before you buy or sell Mirati Therapeutics, Inc. (NASDAQ:MRTX), you may well want to know whether insiders have been buying or selling. What Is Insid...

33

Earnings

-$0.94
-$0.80
-$0.65
-$0.51
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 6, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.